ClinicalTrials.gg
RecruitingNCT06122493Updated Nov 8, 2023

Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma

A Phase 2 interventional study of Tirelizumab and Nab paclitaxel in Esophageal Squamous Cell Carcinoma, sponsored by Ruijin Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-11-08.

Sponsored by Ruijin Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Nov 2022, registered Oct 2023).
  • Started Nov 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma — 13 open to participants now, 15 under way, 1 of them phase 3. tislelizumab · Esophageal Squamous Cell Carcinoma.

Planned enrollment
14th of 23
48 · median 50
Started
2022
with 9 others
Phase 2
14 of 23
8 open now
Primary completion
2026-11
later than 10 of 14 live
Registered
17th of 23
by date

Among the 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma, this one is the 14th largest by planned enrollment, is one of 10 that started in 2022, is one of 14 in phase 2, reaches primary completion later than 10 of the 14 other live ones, and was the 17th registered.

Esophageal Squamous Cell Carcinoma

679 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

13 of the 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma are open now, in 4 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About tislelizumab

tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma, or all of them as a file.
02

Study summary

This study aims to investigate a comprehensive therapeutic approach for patients with unresectable esophageal squamous cell carcinoma, clinically staged as Tany, N3, M0, and who are not candidate for concurrent chemoradiotherapy combined with immunotherapy. The approach entails combining chemotherapy with immune therapy, followed by synchronized radiotherapy during the immune maintenance phase. The primary goal is to mitigate treatment-related side effects and enhance the overall prognosis through the integration of these treatment modalities.

Read the detailed description

Eligible ESCC patients receive a four-cycle regimen of combined chemotherapy plus immunotherapy. Those without disease progression then get definitive radiotherapy with immune maintenance therapy for up to 12 months.

03

Conditions studied

  • Esophageal Squamous Cell Carcinoma

Keywords

  • ESCC
  • cN3
  • radiotherapy
  • chemotherapy
  • immunotherapy
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Esophageal squamous cell carcinoma confirmed through histopathology.
  • Distant excluded by CT, MRI, or PET/CT examinations.
  • Locally advanced stage: AJCC/UICC eighth edition staging with any T, N3M0.
  • Expected survival time of at least 6 months.
  • With an performance status of 0 to 2. Not accompanied by severe pulmonary hypertension, cardiovascular disease, peripheral vascular disease, severe chronic heart disease, or other comorbidities that could impact radiotherapy progress.
  • Adequate function of major organs: Hematopoietic function: ≥100g/L, ≥90×109/L, white blood cells ≥4×109/L. Exceptions may be considered for patients with ECOG 0-1 who have a history of chronic anemia (80-100 g/L), previous low white blood cell levels (3-4×109/L), or reduced platelets (80-90×109/L). Liver function: and AST \<1.5 times the (ULN), \<1.5×ULN. Renal function: Serum creatinine (SCR) ≤140 μmol/L.
  • Patients are required to provide to undergo treatment.

Exclusion criteria

Exclusion Criteria:

  • Existing or prior history of other malignant tumors (except non-melanoma skin cancer) that are uncontrolled or not cured, depending on the type of the primary tumor.
  • Lack of histological or cytological diagnosis for esophageal cancer.
  • Previous chest radiotherapy.
  • Suffering from innate or acquired immune function defects;
  • Pregnancy (confirmed by serum or urine β-HCG test) or during the lactation period; History of drug abuse or alcohol dependence; -positive status, including those on antiretroviral treatment; Chronic with viral replication phase; Active phase of ; Active syphilis with a history of mental illness that may hinder treatment completion.
  • Poor overall health status, defined as \< 70 or > 2.
  • Presence of severe comorbidities that could impact radiotherapy progress, including: Unstable angina, congestive heart failure, or myocardial infarction requiring hospitalization within the past 6 months; Acute bacterial or systemic fungal infections; Exacerbation of or other respiratory conditions requiring hospitalization; Hepatic or renal insufficiency; patients; Coexisting connective tissue diseases, such as active scleroderma or lupus, which are to radiotherapy.
  • Inability to comprehend the treatment's purpose or unwillingness to sign the treatment consent form.
  • Lack of legal capacity or limited legal capacity.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Other
    chemotherapy-immunotherapy-radiotherapy

    Carboplatin (AUC = 5, d1) and nab-paclitaxel (175 mg/m², day1) will be administered every 3 weeks for four cycles.Tislelizumab (200 mg) will be administered every 3 weeks for up to 12 months. Radiotherapy targeting esophageal lesions and positive lymph nodes, with a total dose of 50.4 Gy over 28 fractions will be delivered.

    Drug: Tirelizumab · Drug: Nab paclitaxel · Drug: Carboplatin · Radiation: Radiotherapy

Interventions

  • DrugTislelizumabStudies of TislelizumabTislelizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    immunotherapy, 200 mg on day 1 per 3 weeks

    Also known as: anti-PD-1 monoclonal antibody

  • DrugAlbumin-Bound PaclitaxelStudies of Albumin-Bound PaclitaxelAlbumin-Bound Paclitaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    chemotherapy, 175 mg/m² on day 1 per 3 weeks

    Also known as: Chemotherapy drug

  • chemotherapy, AUC=5 on day 1 per 3 weeks

    Also known as: Chemotherapy drug

  • RadiationRadiotherapy

    Patients without disease progression after four cycles of chemoimmunotherapy receive radiotherapy targeting esophageal lesions and positive lymph nodes, with a total dose of 50.4 Gy delivered over 28 fractions.

    Also known as: Locoregional therapy

06

What researchers measure

Primary outcomes

  1. 1-year progression-free survival

    From the initial administration of the study drug to the first identification of disease progression or mortality, whichever happens first. In the case of patients who had not encountered local control failure or death, specifically in terms of progression-free survival, the time of the last tumor assessment was considered as the endpoint. Tumor response was evaluated by investigators following RECIST v1.1 criteria.

    Time frame: 1 year

Secondary outcomes

  1. Acute toxicity

    Monitor the occurrence of acute toxic reactions (based on CTCAE4.03) and subacute toxic reactions (RTOG) in the treatment of cN3 ESCC with the combination of chemotherapy, immunotherapy, and ongoing radiotherapy, both during the treatment course and within three months after its completion.

    Time frame: 3 months

  2. Quality of Life (QoL)

    Collect QoL data on cN3 ESCC patients. The data is measured by EORTC QLQ-C30 (Version 3.0) according to investigator collection at the starting and ending time of the treatment. EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. The core and disease-specific for ESCC modules are selected to estimate treatment related influence on patients' life. The final score of the questionnaire is collected and analyzed according to detailed scoring procedures from manuals.

    Time frame: 1 years

  3. Objective response rate

    Defined as the proportion of patients with complete response (CR) or partial response (PR)

    Time frame: 1 year

  4. Duration of response

    Defined as the period from the recognition of an objective response to the first identification of either progression or death, whichever event transpired first.

    Time frame: 1 year

  5. Disease control rate

    Defined as the proportion of patients with complete response (CR), partial response (PR) and stable disease (SD)

    Time frame: 1 year

  6. Immune Progression Free Survival

    defined as the duration from the initial dose of tislelizumab to the first identification of either disease progression or death, whichever happens first. Tumor response was evaluated by investigators following iRECIST criteria.

    Time frame: 1 year

  7. Overall survival

    defined as the period from the initial drug administration to the subject's demise from various causes. In cases where patients were lost to follow-up prior to their passing, the date of their last documented contact was documented. For patients still alive at the last analyzed time point, the time of their last contact was considered as their survival duration. In the analysis of survival and subsequent treatment, all patients were monitored until their death, loss to follow-up, or the conclusion of the study.

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Ruijin hospital, Shanghai jiaotong university school of medicine
    Shanghai, Shanghai 200025, China
    Recruiting
    • Shengguang Zhao · Contact
    • Shengguang Zhao · Principal investigator
    • Shuyan Li · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Nov 2026, 48 months after the start.

Of 153 non-industry phase 2 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 55. This study's planned 48 months is above that.

Counting every sponsor, half of 174 studies reached it within 41 months; a quarter within 28 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2023
First posted
Nov 8, 2023
StartActual
Nov 1, 2022
Primary completionEst.
Nov 1, 2026
CompletionEst.
Nov 1, 2026
Last update
Nov 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06122493
Lead sponsor
Ruijin Hospital
Responsible party
Sponsor
First posted
Nov 8, 2023
Start date
Nov 1, 2022
Primary completion
Nov 1, 2026 (estimated)
Completion
Nov 1, 2026 (estimated)
Last update
Nov 8, 2023

Study contacts

Yifeng Wang
Contact
ruijincrc@126.com
0086-021-64370045

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tislelizumab · Albumin-Bound Paclitaxel · Carboplatin

Start the discussion